CClinicalTrials.gg
Sign In
Status unknownNCT05750017Updated Mar 27, 2023

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

A Phase 1 interventional study of Low Dose Recombinant Herpes Zoster Vaccine (LZ901) and High Dose Recombinant Herpes Zoster Vaccine (LZ901) in Herpes Zoster and Vaccine-Preventable Diseases, sponsored by Beijing Luzhu Biotechnology Co., Ltd.. Status unknown at 1 site in United States. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Beijing Luzhu Biotechnology Co., Ltd. · Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

This clinical trial is to study the safety and tolerability of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd. It is a phase I, randomized, double-blind, placebo-controlled, dose escalation study in healthy people aged 50 to 70 years inclusive. The study is to protect adults against shingles (herpes zoster / varicella zoster virus(VZV)). There will be about 66 participators who will receive two-dose injection at the upper arm.

LZ901 vaccine is made up of a tetramer of VZV glycoprotein E (VZV gE-Fc) and adsorbed with aluminum hydroxide adjuvant. This adjuvant can raise the immune response to a lot of antigens. It is the most widely used and safe adjuvant in various types of vaccines worldwide.

In this study:

  1. The participation is voluntary.
  2. Before the study, participants will receive some tests for screening. If qualified, investigators will officially invite them to join this study.
  3. The study vaccine is LZ901 with two different dose levels (50μg/0.5 mL, 100μg/0.5 mL). The placebo, which is saline solution, has no active drug. Participants will receive one of three as above mentioned.
  4. Participants will be enrolled in one of four cohorts. If participants are enrolled in Cohorts 1 or 2, they will receive LZ901. If participants are enrolled in Cohorts 3 or 4, they will have a 2 out of 3 chance (66%) of receiving LZ901 and 1 out of 3 chance (33%) of receiving placebo.
  5. In Cohort 3 and 4, the study staff and participants will not know which study treatment participants will be receiving. However, the study doctor can get this information in case of an emergency.
  6. Participants will stay at the clinic for 30 minutes after each vaccination to observe if there are any uncomfortable.
  7. This study will last about 8 months and will include about 8 study visits to the clinic. During this period, participants will receive a follow-up phone call and/or email by the study staff to follow the condition closely for safety, and record on diary/contact card.
  8. Participants will receive some tests during the study, include safety tests such as physical examination, vital signs measurements, blood tests, urinalysis. Participants will be measured the levels of specific antibodies to see if the vaccine works well.

This study is for research purposes only. Participants may not receive any direct benefits from participating in this study but have a chance to be in a study that may help others in the future.

02

Conditions studied

  • Herpes Zoster
  • Vaccine-Preventable Diseases

Keywords

  • Herpes Zoster
  • Vaccine
03

In context

Herpes Simplex

305 studies on the registry are indexed under Herpes Simplex; 31 are open to participants now.

This study's planned enrollment of 66 is below the median of 101 across 227 interventional studies indexed under Herpes Simplex.

Browse Herpes Simplex studies →

Lead sponsor

Beijing Luzhu Biotechnology Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Males and females able to provide legal identity certificate, aged 50 to 70 years inclusive at the time of signing the ICF;
  2. Able to understand the study procedures, voluntarily agree to participate in the study, and sign the ICF;
  3. Subjects are healthy or have well controlled mild medical conditions as determined by the investigator；

  4. Female subjects are not pregnant or lactating. Female subjects with childbearing potential* should take reliable contraceptive measures**, and have no pregnancy and fertility plan within 7 months;

    *Female subjects of childbearing potential are defined as sexually mature women: 1) have not undergone hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; 2) have had natural menses at any time in the preceding 12 consecutive months (without an alternative medical cause). Post-menopausal should be confirmed with FSH and Estradiol levels.

    **Reliable, medically acceptable forms of contraception:

    • For 3 months prior to screening - hormonal contraceptive (e.g., oral, patch, injectable, depot or vaginal ring), or implantable device (implantable rod or intrauterine device), or
    • For at least 1 month prior to screening - a double barrier method (e.g., diaphragm, cervical cap, or condom in conjunction with spermicide or sponge), or
    • Subjects of reproductive age that are abstinent are acceptable provided they agree to a double barrier method should they become sexually active during the study.
    • and subjects agree to continue birth control for at least 7 months.
  5. Able to attend all scheduled follow-up visits and able to comply with protocol requirements;
  6. Oral temperature \< 37.5℃/99.5℉.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a personal history or family history of convulsion, epilepsy, encephalopathy, and psychosis;
  2. Subjects who received immunosuppressive therapy within 3 months before vaccination (e.g., long-term use of systemic glucocorticoids for ≥ 14 days, dose ≥ 2 mg/kg/day or ≥ 20 mg/day prednisone or equivalence);
  3. Allergic to any component of the investigational vaccine, or have a history of a severe allergy to any vaccination;
  4. Impaired immune function or diagnosed with congenital or acquired immunodeficiency disease, positive serology for Hepatitis B Surface Antigen, Hepatitis C Antibody and human immunodeficiency virus (HIV);
  5. History of varicella or herpes zoster vaccination;
  6. History of HZ;
  7. Received an inactivated or recombinant vaccine within 14 days or any live vaccine within 28 days prior to vaccination;
  8. Subjects who have acute diseases within 3 days before vaccination, or acute stage or exacerbation of chronic diseases within 1 month before vaccination;
  9. Subjects with tattoos to the upper arm deltoid area or have infectious skin disease;
  10. History of thrombocytopenia or other coagulation disorders, which may cause contraindications to intramuscular injection;
  11. History of asplenia or functional asplenia, and asplenia or splenectomy due to any condition;
  12. Subjects with ≥ Grade 2 laboratory abnormalities and Grade 1 laboratory abnormalities that the investigator consider clinically significant;
  13. Participating in other clinical studies of investigational or un-registered products (drugs, vaccines or devices, etc.), or planning to participate in other clinical studies before the end of this clinical study;
  14. Any conditions that in the opinion of the investigator may affect subject safety or assessments (disease factors such as extensive psoriasis, unexplained skin rash, eczema, chronic pain syndrome, or social factors such as plans to move elsewhere before the end of the study).
  15. A positive screen for alcohol, drugs of abuse at screening period and Day 0 (before vaccination).
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Cohort1: Low dose sentinel group

    Three subjects will be first enrolled into low dose sentinel group in open-label, prior to initiation of dosing in each dose level main group.

    Biological: Low Dose Recombinant Herpes Zoster Vaccine (LZ901)

  • Experimental
    Cohort2: High dose sentinel group

    After reviewing the safety through 7 days after the first dose of LZ901, if no safety signals occur, another 3 subjects will be enrolled into high dose sentinel group in open-label.

    Biological: High Dose Recombinant Herpes Zoster Vaccine (LZ901)

  • Placebo comparator
    Cohort3: Low dose main group

    If also no safety signals occur through 7 days after the first dose of LZ901 in high dose sentinel group, 30 subjects will be randomized in a 2:1 ratio to receive two doses of LZ901 or placebo in a double-blind fashion in low dose main group.

    Biological: Low Dose Recombinant Herpes Zoster Vaccine (LZ901) · Drug: Placebo

  • Placebo comparator
    Cohort4: High dose main group

    Subjects will be enrolled in high dose main group also after the safety review through 7 days after the first dose of LZ901 or placebo in low dose main group.

    Biological: High Dose Recombinant Herpes Zoster Vaccine (LZ901) · Drug: Placebo

Interventions

  • BiologicalLow Dose Recombinant Herpes Zoster Vaccine (LZ901)

    0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

  • BiologicalHigh Dose Recombinant Herpes Zoster Vaccine (LZ901)

    0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

  • DrugPlacebo

    0.5 mL per dose, containing 4.5 mg sodium chloride.

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Solicited AEs

    A solicited AE is a pre-specified outcome that the subject is asked to record as present or not. The solicited AEs can be classified as vaccination site (local) AEs and Solicited systemic AEs based on the occurrence site.

    Time frame: From Day 0 through Day 6 after each vaccination.

  2. Unsolicited AEs

    Unsolicited AEs include all AEs, except solicited AEs reported Days 0\~6 after the study intervention.

    Time frame: From Days 0~29 after each vaccination.

  3. AEs leading to withdrawal

    The incidence of AEs leading subjects to withdrawal according to criteria for subject treatment discontinuation and withdrawal from study.

    Time frame: From Day 0 until the outcome is clear after the following up, up to the end of study.

  4. SAEs and MAAEs

    The incidence of all serious adverse events (SAEs) and medically attended adverse events (MAAEs).

    Time frame: From Day 0 through 6 months after the full course vaccination.

  5. Abnormal laboratory tests results

    The incidence of abnormal laboratory tests results.

    Time frame: On Day 3 (+ 1 day) after each study intervention.

Secondary outcomes

  1. The seropositivity rate of anti-gE antibody

    The percentage of seropositive subjects of anti-gE antibody.

    Time frame: On Day 30 after each study intervention.

  2. The seropositivity rate of anti-VZV antibody

    The percentage of seropositive subjects of anti-VZV antibody.

    Time frame: On Day 30 after each study intervention.

  3. Geometric mean concentration (GMC) of anti-gE

    Measured by ELISA.

    Time frame: On Day 30 after each study intervention.

  4. Geometric mean titer (GMT) of anti-VZV

    Measured by fluorescent antibody to the membrane antigen (FAMA).

    Time frame: On Day 30 after each study intervention.

  5. The seroconversion rate of anti-VZV antibody

    Seroconversion refers to at least a 4-fold increase in the anti-VZV antibody titer at the endpoint as compared to the prevaccination concentration (for subjects seropositive pre-vaccination) or a 4-fold increase at the endpoint as compared to the anti-VZV antibody titer cut-off value for seropositivity (for subjects seronegative pre-vaccination).

    Time frame: On Day 30 after each study intervention.

  6. The seroconversion rate of anti-gE antibody

    Seroconversion refers to at least a 4-fold increase in the anti-gE Ab concentration at the endpoint as compared to the prevaccination concentration (for subjects seropositive pre-vaccination) or a 4-fold increase at the endpoint as compared to the anti-gE Ab cut-off value for seropositivity (for subjects seronegative pre-vaccination).

    Time frame: On Day 30 after each study intervention.

  7. Change of anti-Fc antibody

    Change of anti-Fc antibody on Day 30 after each study intervention compared with pre-immunization.

    Time frame: From pre-immunization to Day 30 after each study intervention.

07

Study locations

1 of 1 sites recruiting
  • Frontage Clinical Services, Inc.
    Secaucus, New Jersey 07094, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05750017
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Mar 1, 2023
Start date
Mar 23, 2023
Primary completion
Feb 1, 2024 (estimated)
Completion
Mar 15, 2024 (estimated)
Last update
Mar 27, 2023

Study contacts

Frank Lee, MD
Contact
flee@frontagelab.com
(201) 416-7745 ext. (201) 416-7753
Sumitha Reddy, MD
Contact
sreddy@frontagelab.com
(201) 416-7760
Frank Lee, MD
principal investigator · Frontage Clinical Services, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Herpes Simplex→

Other studies from this sponsor

Beijing Luzhu Biotechnology Co., Ltd.

Start the discussion